The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice
文献类型：期刊论文
| 作者 | Hu, Miao-miao1; Zhang, Jie1; Wang, Wen-yi1; Wu, Wen-yu1; Ma, Yan-ling1; Chen, Wei-hai2,3; Wang, Yi-ping1
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2011-10 |
| 卷号 | 32期号:10页码:1253-1258 |
| 关键词 | atherosclerosis lp-PLA2 darapladib LDLR-deficient mice inflammation high-sensitivity C-reactive protein interleukin-6 monocyte chemotactic protein-1 vascular cell adhesion molecule-1 |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/aps.2011.127 |
| 文献子类 | Article |
| 英文摘要 | Aim: To investigate the effects of darapladib, a specific inhibitor of lipoprotein-associated phospholipase A2 (lp-PLA2), on inflammation and atherosclerotic formation in the low density lipoprotein receptor (LDLR)-deficient mice. Methods: Six-week-old LDLR-deficient mice were fed an atherogenic high-fat diet for 17 weeks and then randomly divided into two groups. One group was administered darapladib (50 mg.kg(-1).d(-1); po) for 6 weeks. The other group was administered saline as a control. Serum lipid levels were measured using the corresponding kits, and three inflammatory markers - interleukin-6 (IL-6), C reactive protein (hs-CRP), and platelet activating factor (PAF) - were determined using ELISA. Atherosclerotic plaque areas were stained with Sudan IV, and inflammatory gene expression at the lesions was evaluated using quantitative real-time PCR. Results: The body weight and serum lipid level between the two groups were similar at the end of the dietary period. The serum lp-PLA2 activity, hs-CRP and IL-6 levels, however, were significantly reduced in the darpladib group. The inhibition of lp-PLA2 did not alter the serum PAF level. Furthermore, the plaque area, from the aortic arch to the abdominal aorta, was significantly reduced in the darpladib group. Additionally, the expression of inflammatory genes monocyte chemotactic protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) was significantly reduced at the lesions in the darapladib group. Conclusion: Inhibition of lp-PLA2 by darapladib decreases the inflammatory burden and atherosclerotic plaque formation in LDLR-deficient mice, which may be a new strategy for the treatment of atherosclerosis. |
| WOS关键词 | PLATELET-ACTIVATING-FACTOR ; CORONARY-HEART-DISEASE ; LOW-DENSITY-LIPOPROTEIN ; C-REACTIVE PROTEIN ; MIDDLE-AGED MEN ; FACTOR-ACETYLHYDROLASE ; OXIDIZED PHOSPHOLIPIDS ; CARDIOVASCULAR EVENTS ; ARTERY-DISEASE ; RISK-FACTORS |
| 资助项目 | Shanghai Committee of Science and Technology, China[11ZR1444800] ; National Basic Research Program of China[2009CB930300] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| CSCD记录号 | CSCD:4335575 |
| WOS记录号 | WOS:000295921300010 |
| 出版者 | ACTA PHARMACOLOGICA SINICA |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/278382]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Wang, Yi-ping |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Dept Pharmacol 1, Shanghai 201203, Peoples R China; 2.Southwest Univ, Minist Educ, Key Lab Cognit & Personal SWU, Chongqing 400715, Peoples R China; 3.Southwest Univ, Sch Psychol, Chongqing 400715, Peoples R China |
| 推荐引用方式 GB/T 7714 | Hu, Miao-miao,Zhang, Jie,Wang, Wen-yi,et al. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice[J]. ACTA PHARMACOLOGICA SINICA,2011,32(10):1253-1258. |
| APA | Hu, Miao-miao.,Zhang, Jie.,Wang, Wen-yi.,Wu, Wen-yu.,Ma, Yan-ling.,...&Wang, Yi-ping.(2011).The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.ACTA PHARMACOLOGICA SINICA,32(10),1253-1258. |
| MLA | Hu, Miao-miao,et al."The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice".ACTA PHARMACOLOGICA SINICA 32.10(2011):1253-1258. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。